Women with extremely dense breasts are at a higher risk of breast cancer, and the sensitivity of mammography in this group is reduced due to the masking effect of overlapping tissue. This review examines supplemental screening methods to improve detection in this population, with a focus on MRI. Morphologic techniques offer limited benefits, digital breast tomosynthesis (DBT) shows inconsistent results, and ultrasound (US), while improving cancer detection rates (CDR), results in a higher rate of false positives. Functional imaging techniques show better performance, molecular breast imaging increases CDR but is limited in availability, and contrast-enhanced mammography is promising, with good results and as an accessible technique, but requires further validation. MRI, with sensitivity ranging from 81% to 100%, is the most supported modality. Despite strong evidence for MRI in this population, high costs, use of contrast, and longer scan times hinder widespread use. Abbreviated MRI protocols aim to overcome these barriers by reducing costs and scan duration. As personalized screening becomes a future focus, MRI remains the most effective option for women with extremely dense breasts. LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY: Stage 5.
This review covers the theoretical background, pulse sequence considerations, practical implementations, and multitudes of applications of magnetic resonance acoustic radiation force imaging (MR-ARFI) described to date. MR-ARFI is an approach to encode tissue displacement caused by the acoustic radiation force of a focused ultrasound field into the phase of a MR image. The displacement encoding is done with motion encoding gradients (MEG) which have traditionally been added to spin echo-type and gradient recalled echo-type pulse sequences. Many different types of MEG (monopolar, bipolar, tripolar etc.) have been described and pros and cons are discussed. We further review studies investigating the safety of MR-ARFI, as well as approaches to simulate the MR-ARFI displacement. Lastly, MR-ARFI applications such as for focal spot localization, tissue stiffness interrogation following thermal ablation, trans-skull aberration correction, and simultaneous MR-ARFI and MR thermometry are discussed. EVIDENCE LEVEL: N/A TECHNICAL EFFICACY: Stage 1.
The biochemical composition and structure of the brain are in a rapid change during the exuberant stage of fetal and neonatal development. 1H-MRS is a noninvasive tool that can evaluate brain metabolites in healthy fetuses and infants as well as those with neurological diseases. This review aims to provide readers with an understanding of 1) the basic principles and technical considerations relevant to 1H-MRS in the fetal-neonatal brain and 2) the role of 1H-MRS in early fetal-neonatal development brain research. We performed a PubMed search to identify original studies using 1H-MRS in neonates and fetuses to establish the clinical applications of 1H-MRS. The eligible studies for this review included original research with 1H-MRS applications to the fetal-neonatal brain in healthy and high-risk conditions. We ran our search between 2000 and 2023, then added in several high-impact landmark publications from the 1990s. A total of 366 results appeared. After, we excluded original studies that did not include fetuses or neonates, non-proton MRS and non-neurological studies. Eventually, 110 studies were included in this literature review. Overall, the function of 1H-MRS in healthy fetal-neonatal brain studies focuses on measuring the change of metabolite concentrations during neurodevelopment and the physical properties of the metabolites such as T1/T2 relaxation times. For high-risk neonates, studies in very low birth weight preterm infants and full-term neonates with hypoxic-ischemic encephalopathy, along with examining the associations between brain biochemistry and cognitive neurodevelopment are most common. Additional high-risk conditions included infants with congenital heart disease or metabolic diseases, as well as fetuses of pregnant women with hypertensive disorders were of specific interest to researchers using 1H-MRS. EVIDENCE LEVEL: 1 TECHNICAL EFFICACY: Stage 2.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：